Compare NIU & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | MNOV |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 137.8M |
| IPO Year | 2018 | 2004 |
| Metric | NIU | MNOV |
|---|---|---|
| Price | $1.89 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.55 | ★ $8.25 |
| AVG Volume (30 Days) | 181.7K | ★ 377.8K |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $20.29 | $78.20 |
| Revenue Next Year | $22.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $1.79 | $1.17 |
| 52 Week High | $4.58 | $3.90 |
| Indicator | NIU | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 36.25 |
| Support Level | $1.81 | $1.29 |
| Resistance Level | $2.04 | $1.48 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 48.15 | 5.10 |
Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.